Quality in Sport
Cure8 research brief
Why This Matters
GLP-1 and dual GIP/GLP-1 agonists are being studied as treatments that could help people with IBD who also have obesity or metabolic problems by reducing weight and inflammation without clearly worsening IBD. This could affect symptoms, flare risk, and need for steroids or surgery.
Who Should Pay Attention
Adults with IBD plus obesity/metabolic disease; gastroenterologists and IBD clinicians; obesity specialists and researchers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article is a literature review (abstract-level summary) examining GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 agonist tirzepatide in people with inflammatory bowel disease (IBD) and obesity/metabolic disorders.
The review reports that incretin-based therapies have immunomodulatory and intestinal barrier–protective effects and that real-world studies and meta-analyses showed weight loss, lower CRP, reduced hospitalizations, less corticosteroid use, and lower IBD-related surgery rates.
It also notes these drugs were generally well tolerated with no clear increased risk of IBD exacerbations, but delayed gastric emptying and potential interactions (e.g., with oral thiopurines) are important considerations.
Ongoing randomized trials are mentioned as needed to define their role in gastroenterology guidelines; this article summarizes existing studies rather than presenting new trial results.
Keep In Mind
Summary is based on the article's abstract-level review of 20 studies and notes ongoing randomized trials; it does not present primary trial data. Be cautious about generalizing observational/meta-analytic findings to all patients; drug–drug interactions (e.g., with oral thiopurines) were highlighted.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationQuality in Sport
PublisherUniwersytet Mikolaja Kopernika/Nicolaus Copernicus University
AuthorsMichał Antoni Dróżdż, Maria Marcak, Weronika Nowicka +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 2, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...
Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.
People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear...
Preclinical and limited clinical evidence for metformin in ulcerative colitis: a systematic review and meta-analysis
Metformin is a common, inexpensive drug with possible anti-inflammatory effects; this review compiles preclinical and early clinical data suggesting it might influence ulcerative colitis biology. Readers may want to know...